Clinical Research Directory
Browse clinical research sites, groups, and studies.
CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure
Sponsor: NYU Langone Health
Summary
The proposed trial is a single arm, non-randomized, single center pilot study utilizing CliniMACS CD34 Reagent System for patients following allogeneic hematopoietic stem cell transplant (HSCT) requiring treatment of graft dysfunction or failure.
Official title: CD34+ Selected Donor Cell Boost for Management of Poor Graft Function or Primary or Secondary Graft Failure Following Allogeneic Hematopoietic Stem Cell Transplantation
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
21
Start Date
2024-10-31
Completion Date
2035-08
Last Updated
2025-09-29
Healthy Volunteers
No
Conditions
Interventions
CD34+ Selected Donor Cell Boost
The CliniMACS CD34 Reagent System is used to separate CD34 cells from the remaining stem cell product, using a peripheral blood stem cell sample provided by the original donor. These CD34 cells are then infused into the recipient following selection with the intent to restore function of the blood forming cells.
Blood Stem Cell Infusion
The selected CD34 cells separated by the CliniMACS CD34 Reagent System are infused into the recipient.
Locations (1)
NYU Langone Health
New York, New York, United States